Amicus Therapeutics (FOLD) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

FOLD Stock Forecast

Amicus Therapeutics stock forecast is as follows: an average price target of $15.25 (represents a 57.54% upside from FOLD’s last price of $9.68) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.

FOLD Price Target

The average price target for Amicus Therapeutics (FOLD) is $15.25 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $19.00 to $13.00. This represents a potential 57.54% upside from FOLD's last price of $9.68.

FOLD Analyst Ratings

Buy

According to 7 Wall Street analysts, Amicus Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for FOLD stock is 0 'Strong Buy' (0.00%), 6 'Buy' (85.71%), 0 'Hold' (0.00%), 1 'Sell' (14.29%), and 0 'Strong Sell' (0.00%).

Amicus Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Oct 17, 2024	Tazeen Ahmad	Bank of America Securities	$15.00	$12.03	24.69%	54.96%
May 14, 2024	Debjit Chattopadhyay	Guggenheim	$13.00	$9.04	43.81%	34.30%
May 09, 2024	Jeffrey Hung	Morgan Stanley	$19.00	$9.48	100.42%	96.28%
Dec 19, 2023	Jeffrey Hung	Morgan Stanley	$20.00	$12.66	57.98%	106.61%
May 10, 2021	Salveen Richter	Goldman Sachs	$14.00	$9.39	49.09%	44.63%

Row per page

Go to

The latest Amicus Therapeutics stock forecast, released on Oct 17, 2024 by Tazeen Ahmad from Bank of America Securities, set a price target of $15.00, which represents a 24.69% increase from the stock price at the time of the forecast ($12.03), and a 54.96% increase from FOLD last price ($9.68).

Amicus Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	-	1	4
Avg Price Target	-	$15.00	$16.75
Last Closing Price	$9.68	$9.68	$9.68
Upside/Downside	-100.00%	54.96%	73.04%

In the current month, the average price target of Amicus Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Amicus Therapeutics's last price of $9.68. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 23, 2024	Cowen & Co.	Buy	Buy	Hold
Oct 17, 2024	Bank of America Securities	Buy	Buy	Hold
Oct 11, 2024	Jefferies	Buy	Buy	Hold
Oct 11, 2024	Cantor Fitzgerald	Underperform	Underperform	Hold
Sep 06, 2024	Jefferies	-	Buy	Initialise
Jul 22, 2024	Cowen & Co.	Buy	Buy	Hold
May 30, 2024	Wells Fargo	-	Overweight	Initialise
May 14, 2024	UBS	Buy	Buy	Hold
May 14, 2024	Guggenheim	Underperform	Underperform	Hold
May 14, 2024	Guggenheim	-	Buy	Upgrade

Row per page

Go to

Amicus Therapeutics's last stock rating was published by Cowen & Co. on Oct 23, 2024. The company gave FOLD a "Buy" rating, the same as its previous rate.

Amicus Therapeutics Financial Forecast

Amicus Therapeutics Revenue Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$103.50M	-	$86.27M	$88.10M	$81.69M	$80.73M	$78.72M	$82.15M	$79.55M	$77.41M	$66.40M	$70.57M	$67.44M
Avg Forecast	$258.00M	$242.00M	$229.00M	$221.00M	$222.00M	$207.00M	$194.00M	$181.00M	$181.62M	$167.35M	$153.74M	$142.00M	$147.37M	$134.93M	$121.21M	$111.19M	$114.35M	$102.30M	$89.83M	$83.18M	$86.31M	$84.21M	$85.87M	$77.18M	$83.41M	$80.11M	$73.16M	$71.70M	$69.56M	$64.81M
High Forecast	$266.01M	$249.52M	$236.11M	$227.86M	$228.90M	$213.43M	$200.03M	$186.62M	$187.26M	$172.55M	$158.52M	$146.03M	$149.69M	$135.01M	$121.21M	$111.19M	$114.43M	$102.30M	$92.62M	$85.77M	$88.99M	$84.21M	$85.87M	$77.18M	$83.41M	$80.11M	$73.16M	$71.70M	$69.56M	$64.81M
Low Forecast	$252.03M	$236.40M	$223.70M	$215.88M	$216.86M	$202.21M	$189.51M	$176.81M	$177.41M	$163.48M	$150.19M	$138.76M	$144.86M	$134.84M	$121.21M	$111.19M	$114.27M	$102.30M	$87.75M	$81.26M	$84.31M	$84.21M	$85.87M	$77.18M	$83.41M	$80.11M	$73.16M	$71.70M	$69.56M	$64.81M
# Analysts	3	3	3	3	3	3	3	3	4	4	4	6	9	4	3	4	7	5	6	3	2	2	2	2	3	4	5	6	5	5
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.01%	-	1.04%	1.02%	0.97%	0.94%	1.02%	0.98%	0.99%	1.06%	0.93%	1.01%	1.04%

Amicus Therapeutics's average Quarter revenue forecast for Dec 23 based on 7 analysts is $114.35M, with a low forecast of $114.27M, and a high forecast of $114.43M. FOLD's average Quarter revenue forecast represents a 10.48% increase compared to the company's last Quarter revenue of $103.50M (Sep 23).

Amicus Therapeutics EBITDA Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	3	3	3	3	3	3	3	3	4	4	4	6	9	4	3	4	7	5	6	3	2	2	2	2	3	4	5	6	5	5
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-29.21M	-	$-39.87M	$-56.09M	$-17.79M	$-51.54M	$-66.47M	$-70.61M	$-40.79M	$-36.98M	$-54.49M	$-62.77M	$-54.00M
Avg Forecast	$-177.10M	$-166.12M	$-157.19M	$-151.70M	$-152.39M	$-142.09M	$-133.17M	$-124.24M	$-124.67M	$-114.87M	$-105.54M	$-97.47M	$-101.16M	$-92.62M	$-83.21M	$-80.03M	$-78.49M	$-70.22M	$-61.66M	$-63.27M	$-50.33M	$-55.25M	$-56.34M	$-57.51M	$-54.72M	$-52.56M	$-48.00M	$-52.22M	$-45.64M	$-42.52M
High Forecast	$-173.00M	$-162.27M	$-153.55M	$-148.19M	$-148.86M	$-138.80M	$-130.09M	$-121.37M	$-121.78M	$-112.22M	$-103.09M	$-95.25M	$-99.44M	$-92.56M	$-83.21M	$-64.03M	$-78.44M	$-70.22M	$-60.24M	$-50.61M	$-40.26M	$-55.25M	$-56.34M	$-46.01M	$-54.72M	$-52.56M	$-48.00M	$-41.77M	$-45.64M	$-42.52M
Low Forecast	$-182.60M	$-171.28M	$-162.08M	$-156.41M	$-157.12M	$-146.51M	$-137.31M	$-128.10M	$-128.54M	$-118.44M	$-108.81M	$-100.24M	$-102.75M	$-92.68M	$-83.21M	$-96.04M	$-78.55M	$-70.22M	$-63.58M	$-75.92M	$-60.39M	$-55.25M	$-56.34M	$-69.02M	$-54.72M	$-52.56M	$-48.00M	$-62.66M	$-45.64M	$-42.52M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.42%	-	0.63%	1.11%	0.32%	0.91%	1.16%	1.29%	0.78%	0.77%	1.04%	1.38%	1.27%

undefined analysts predict FOLD's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Amicus Therapeutics's previous annual EBITDA (undefined) of $NaN.

Amicus Therapeutics Net Income Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	3	3	3	3	3	3	3	3	4	4	4	6	9	4	3	4	7	5	6	3	2	2	2	2	3	4	5	6	5	5
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-21.58M	-	$-52.93M	$-55.87M	$-33.29M	$-62.16M	$-85.26M	$-83.28M	$-50.29M	$-51.23M	$-65.66M	$-71.40M	$-64.01M
Avg Forecast	-	-	-	-	-	-	-	-	$25.53M	$16.51M	$10.14M	$-743.45K	$5.48M	$360.14K	$-16.73M	$-94.91M	$-17.62M	$-23.12M	$-34.72M	$-75.03M	$-59.35M	$-57.33M	$-64.06M	$-68.21M	$-47.50M	$-53.38M	$-65.65M	$-62.93M	$-69.77M	$-64.52M
High Forecast	-	-	-	-	-	-	-	-	$26.56M	$17.17M	$10.55M	$-424.83K	$8.77M	$374.69K	$-16.22M	$-75.93M	$-2.94M	$-22.43M	$-33.67M	$-60.02M	$-47.48M	$-57.33M	$-64.06M	$-54.57M	$-47.50M	$-53.38M	$-65.65M	$-50.34M	$-69.77M	$-64.52M
Low Forecast	-	-	-	-	-	-	-	-	$24.76M	$16.01M	$9.84M	$-1.17M	$1.10M	$349.30K	$-17.40M	$-113.89M	$-26.43M	$-24.06M	$-36.12M	$-90.03M	$-71.22M	$-57.33M	$-64.06M	$-81.85M	$-47.50M	$-53.38M	$-65.65M	$-75.51M	$-69.77M	$-64.52M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.93%	-	0.71%	0.94%	0.58%	0.97%	1.25%	1.75%	0.94%	0.78%	1.04%	1.02%	0.99%

Amicus Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. FOLD's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Amicus Therapeutics SG&A Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	3	3	3	3	3	3	3	3	4	4	4	6	9	4	3	4	7	5	6	3	2	2	2	2	3	4	5	6	5	5
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$65.65M	-	$73.96M	$54.27M	$47.27M	$53.38M	$58.12M	$57.60M	$46.11M	$42.28M	$46.73M	$43.69M	$37.85M
Avg Forecast	$180.54M	$169.34M	$160.24M	$154.64M	$155.34M	$144.85M	$135.75M	$126.65M	$127.09M	$117.10M	$107.58M	$99.36M	$103.12M	$94.42M	$84.82M	$64.69M	$80.01M	$71.58M	$62.86M	$51.14M	$41.05M	$58.93M	$60.09M	$46.49M	$58.36M	$56.06M	$51.19M	$44.78M	$48.67M	$45.35M
High Forecast	$186.14M	$174.60M	$165.22M	$159.45M	$160.17M	$149.35M	$139.97M	$130.59M	$131.04M	$120.74M	$110.92M	$102.18M	$104.75M	$94.48M	$84.82M	$77.63M	$80.07M	$71.58M	$64.81M	$61.37M	$49.26M	$58.93M	$60.09M	$55.79M	$58.36M	$56.06M	$51.19M	$53.73M	$48.67M	$45.35M
Low Forecast	$176.36M	$165.42M	$156.53M	$151.06M	$151.75M	$141.49M	$132.61M	$123.72M	$124.15M	$114.39M	$105.09M	$97.10M	$101.37M	$94.36M	$84.82M	$51.76M	$79.96M	$71.58M	$61.40M	$40.91M	$32.84M	$58.93M	$60.09M	$37.19M	$58.36M	$56.06M	$51.19M	$35.82M	$48.67M	$45.35M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.92%	-	1.45%	1.32%	0.80%	0.89%	1.25%	0.99%	0.82%	0.83%	1.04%	0.90%	0.83%

Amicus Therapeutics's average Quarter SG&A projection for Dec 23 is $80.01M, based on 7 Wall Street analysts, with a range of $79.96M to $80.07M. The forecast indicates a 21.88% rise compared to FOLD last annual SG&A of $65.65M (Sep 23).

Amicus Therapeutics EPS Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	3	3	3	3	3	3	3	3	4	4	4	6	9	4	3	4	7	5	6	3	2	2	2	2	3	4	5	6	5	5
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.00	-	$-0.18	$-0.19	$-0.12	$-0.21	$-0.30	$-0.31	$-0.19	$-0.19	$-0.25	$-0.28	$-0.25
Avg Forecast	-	-	-	-	-	-	-	-	$0.08	$0.05	$0.03	$-0.00	$0.02	-	$-0.05	$-0.06	$-0.06	$-0.08	$-0.11	$-0.14	$-0.12	$-0.19	$-0.21	$-0.25	$-0.16	$-0.18	$-0.22	$-0.24	$-0.23	$-0.21
High Forecast	-	-	-	-	-	-	-	-	$0.09	$0.06	$0.03	$-0.00	$0.03	-	$-0.05	$-0.06	$-0.01	$-0.07	$-0.11	$-0.13	$-0.11	$-0.19	$-0.21	$-0.25	$-0.16	$-0.18	$-0.22	$-0.24	$-0.23	$-0.21
Low Forecast	-	-	-	-	-	-	-	-	$0.08	$0.05	$0.03	$-0.00	-	-	$-0.06	$-0.07	$-0.09	$-0.08	$-0.12	$-0.14	$-0.12	$-0.19	$-0.21	$-0.25	$-0.16	$-0.18	$-0.22	$-0.24	$-0.23	$-0.21
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00%	-	1.32%	1.62%	0.64%	1.00%	1.18%	1.98%	1.08%	0.88%	1.03%	1.20%	1.18%

According to undefined Wall Street analysts, Amicus Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to FOLD previous annual EPS of $NaN (undefined).

Amicus Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
ARVN	Arvinas	$22.48	$71.82	219.48%	Buy
DAWN	Day One Biopharmaceuticals	$13.31	$38.80	191.51%	Buy
MLYS	Mineralys Therapeutics	$11.48	$30.00	161.32%	Buy
RARE	Ultragenyx Pharmaceutical	$44.75	$106.93	138.95%	Buy
LEGN	Legend Biotech	$38.19	$82.69	116.52%	Buy
MREO	Mereo BioPharma Group	$3.53	$6.75	91.22%	Buy
CYTK	Cytokinetics	$50.22	$83.23	65.73%	Buy
KURA	Kura Oncology	$15.92	$26.00	63.32%	Buy
BMRN	BioMarin Pharmaceutical	$63.42	$101.70	60.36%	Buy
DNLI	Denali Therapeutics	$25.05	$40.00	59.68%	Buy
FOLD	Amicus Therapeutics	$9.68	$15.25	57.54%	Buy
DYN	Dyne Therapeutics	$28.39	$43.88	54.56%	Buy
HRMY	Harmony Biosciences	$33.22	$48.86	47.08%	Buy
EWTX	Edgewise Therapeutics	$31.44	$45.00	43.13%	Buy
CRNX	Crinetics Pharmaceuticals	$54.72	$70.14	28.18%	Buy
DICE	DICE Therapeutics	$47.55	$60.00	26.18%	Buy
BPMC	Blueprint Medicines	$88.69	$109.71	23.70%	Buy
INCY	Incyte	$75.87	$84.56	11.45%	Buy
RVMD	Revolution Medicines, Inc. Warrant	$55.13	$60.63	9.98%	Buy
AGIO	Agios Pharmaceuticals	$53.78	$48.00	-10.75%	Buy
ARGX	argenx SE	$564.23	$475.14	-15.79%	Buy
KRTX	Karuna Therapeutics	$329.83	$257.50	-21.93%	Buy

FOLD Forecast FAQ

Is Amicus Therapeutics a good buy?

Yes, according to 7 Wall Street analysts, Amicus Therapeutics (FOLD) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 85.71% of FOLD's total ratings.

What is FOLD's price target?

Amicus Therapeutics (FOLD) average price target is $15.25 with a range of $13 to $19, implying a 57.54% from its last price of $9.68. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Amicus Therapeutics stock go up soon?

According to Wall Street analysts' prediction for FOLD stock, the company can go up by 57.54% (from the last price of $9.68 to the average price target of $15.25), up by 96.28% based on the highest stock price target, and up by 34.30% based on the lowest stock price target.

Can Amicus Therapeutics stock reach $15?

FOLD's average twelve months analyst stock price target of $15.25 supports the claim that Amicus Therapeutics can reach $15 in the near future.

What are Amicus Therapeutics's analysts' financial forecasts?

Amicus Therapeutics's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $804M (high $828.97M, low $785.38M), average EBITDA is $-552M (high $-539M, low $-569M), average net income is $0 (high $0, low $0), average SG&A $562.6M (high $580.07M, low $549.57M), and average EPS is $0 (high $0, low $0). FOLD's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $950M (high $979.51M, low $928M), average EBITDA is $-652M (high $-637M, low $-672M), average net income is $0 (high $0, low $0), average SG&A $664.76M (high $685.41M, low $649.37M), and average EPS is $0 (high $0, low $0).

Did the FOLD's actual financial results beat the analysts' financial forecasts?

Based on Amicus Therapeutics's last annual report (Dec 2023), the company's revenue was $399.36M, beating the average analysts forecast of $389.66M by 2.49%. Apple's EBITDA was $-195M, missing the average prediction of $-274M by -28.61%. The company's net income was $-152M, beating the average estimation of $-150M by 0.73%. Apple's SG&A was $275.27M, beating the average forecast of $265.6M by 3.64%. Lastly, the company's EPS was $-514, beating the average prediction of $-0.384 by 133469.84%. In terms of the last quarterly report (Sep 2023), Amicus Therapeutics's revenue was $103.5M, beating the average analysts' forecast of $102.3M by 1.18%. The company's EBITDA was $-29.207M, missing the average prediction of $-70.22M by -58.41%. Amicus Therapeutics's net income was $-21.577M, missing the average estimation of $-23.122M by -6.68%. The company's SG&A was $65.65M, missing the average forecast of $71.58M by -8.29%. Lastly, the company's EPS was $-0.0001, missing the average prediction of $-0.0759 by -99.87%